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Abstract
Objective: We assessed the 18-month effectiveness of short-course (sc) antiretroviral peripartum regimens combined with
alternatives to prolonged breastfeeding to prevent mother-to-child transmission (MTCT) of HIV-1 in Abidjan, Co ˆte d’Ivoire.
Methodology: HIV-1 infected pregnant women received from $32–36 weeks of gestation scZidovudine (ZDV)+/
2Lamivudine (3TC)+single-dose Nevirapine (sdNVP) at delivery within the ANRS 1201/1202 DITRAME-Plus cohort (2001–
2003). Neonates received a sdNVP+7-day ZDV prophylaxis. Two infant-feeding interventions were systematically offered free
of charge: formula-feeding or exclusive shortened breastfeeding with early cessation from four months. The reference
group was the ANRS 049a DITRAME cohort (1994–2000) exposed to scZDV from 36 weeks, then to prolonged breastfeeding.
Pediatric HIV infection was defined by a positive plasma HIV-1 RNA at any age, or if aged $18 months, a positive HIV-1
serology. Turnbull estimates of cumulative transmission risks (CTR) and effectiveness (HIV-free survival) were compared by
exposure group using a Cox model.
Findings: Among 926 live-born children enrolled, 107 (11.6%) were HIV-infected at 18 months. CTRs were 22.3% (95%
confidence interval[CI]:16–30%) in the 238 ZDV long-term breastfed reference group, 15.9% (CI:10–27%) in the 169
ZDV+sdNVP shortened breastfed group; 9.4% (CI:6–14%) in the 195 ZDV+sdNVP formula-fed group; 6.8% (CI:4–11%) in the
198 ZDV+3TC+sdNVP shortened breastfed group, and 5.6% (CI:2–10%) in the 126 ZDV+3TC+sdNVP formula-fed group. Each
combination had a significantly higher effectiveness than the ZDV long-term breastfed group except for ZDV+sdNVP
shortened breastfed children, ranging from 51% (CI:20–70%) for ZDV+sdNVP formula fed children to 63% (CI:40–80%) for
ZDV+3TC+NVPsd shortened breastfed children, after adjustment for maternal eligibility for antiretroviral therapy (ART),
home delivery and low birth-weight. Substantial MTCT risk reductions are reachable in Africa, even in short-term breastfed
children. The two sc antiretroviral combinations associated to any of the two infant feeding interventions, formula-feeding
and shortened breastfeeding, reduce significantly MTCT with long-term benefit until age 18 months and without increasing
mortality.
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Introduction
In African randomized clinical trials, several short-course (sc) or
single-dose (sd) antiretroviral (ARV) regimens administered
around the time of delivery (peripartum) have demonstrated a
short-term efficacy to prevent mother-to-child transmission
(PMTCT) of HIV-1, as estimated at age 6–8 weeks of life
[1,2,3,4]. An African pooled meta-analysis suggested the greater
efficacy of ARV combinations than with any single ARV drug
strategy [5]. All these scARV regimens using zidovudine (ZDV),
lamivudine (3TC) or nevirapine (NVP) have been recommended
for public health use in HIV-infected women and neonates in
World Health Organization (WHO) evidence-based guidelines
since 2000 [6].
PLoS ONE | www.plosone.org 1 February 2008 | Volume 3 | Issue 2 | e1645However, in 2007, it is also well acknowledged that the
subsequent risk of postnatal transmission of HIV-1 via breastfeed-
ing is high in African populations where prolonged breastfeeding is
the norm and may reduce the long-term efficacy of peripartum
ARV regimens [6]. This long-term efficacy was shown to be still
significantly sustained although lowered at age 24 months for
scZDV [7] and at age 18-month for sdNVP but little benefit
remained at 18-month using different regimens of scZDV+3TC
[3]. It is therefore crucial to assess the long–term endpoints to fully
measure ARV efficacy in breastfed populations. In addition,
scARV regimens to prevent peripartum transmission should be
complemented by postnatal interventions to reduce HIV trans-
mission through breastfeeding and maximize their long-term
combined efficacy. Among the different postnatal interventions,
alternatives to prolonged breastfeeding, such as formula-feeding or
exclusive breastfeeding with early cessation are two conceivable
options in African urban settings where clean water is widely
available. In these settings, field effectiveness of these interventions
could be defined using a combined outcome, HIV-free survival, to
assess their field efficacy in reducing MTCT taking into account
the risk of alternatives to prolonged breastfeeding.
From March 2001 to March 2003, before the antiretroviral
therapy access, we enrolled an open-label cohort study in Abidjan,
Co ˆte d’Ivoire to evaluate the acceptability, tolerance and field
efficacy of a PMTCT package systematically offered to HIV-1
infected pregnant women: 1/two peripartum ARV interventions
were successively introduced: ZDV+sdNVP during labor, followed
by a short neonatal prophylaxis of ZDV+sdNVP; or the same
regimen with the addition of a maternal 3TC [8]; 2/two post-
partum infant feeding options were simultaneously offered:
exclusive formula-feeding or shortened exclusive breastfeeding
during four months [9,10,11]. In this paper, we report on the 18-
month effectiveness (HIV-free survival) of these two combined
PMTCT interventions; and compare them to an historical group
followed in the same population and exposed to ZDV only with
unrestricted prolonged breastfeeding.
Methods
Study sites
The ANRS 1201/1202 Ditrame-Plus project was conducted in
community-run facilities in two urban districts of Abidjan, Co ˆte
d’Ivoire where HIV-1 seroprevalence in pregnant women was
estimated to be around 11% in 2001–2003 [12].
Study design
The study design was a non-randomized open-label prospective
cohort [8,9,10,11]. The peripartum ARV intervention was
followed by one of the two infant feeding options then completed
by the case management of HIV-infected children including
cotrimoxazole prophylaxis. No maternal or pediatric antiretroviral
therapy (ART) other than the study drugs for PMTCT indications
was available at that time in Co ˆte d’Ivoire. The study protocol
was approved by the Ethics Committee of the National AIDS
Control Program in Co ˆte d’Ivoire and the Institutional Review
Board of the French Agence Nationale de Recherches sur le SIDA
(ANRS).
Inclusion procedures
All consenting pregnant women attending the selected prenatal
clinics, living within the city limits, presenting at ,36 weeks of
gestation, age $18 years, HIV-1 or HIV-1+2-infected, with
hemoglobinemia $7 g/dl, and having signed an informed consent
were systematically included [8,13,14].
Study interventions
Women included received subsequently a peripartum ARV
regimen as follows [8]: from 2001 to 2002, oral ZDV from 36
weeks of gestation daily and sdNVP at beginning of labor followed
by a neonatal post-exposure prophylaxis: directly observed sdNVP
on Day 2 and a seven-day course of ZDV syrup; from 2002 to
2003, the same maternal regimen was given from 32 weeks of
gestation with the addition of 3TC. The ZDV+3TC maternal
regimen was continued for three days post-partum. The neonatal
regimen remained unchanged. Women received a supplementa-
tion in multivitamins [15], iron and folates, and malaria
chemoprophylaxis according to Ivorian guidelines.
At inclusion, all pregnant women were individually counseled
about both the advantages of breast-milk and the risk of HIV
postnatal transmission. They were then systematically offered two
alternative options to prolonged breastfeeding: exclusive formula-
feeding from birth (with a drug inhibiting lactation) or exclusive
shortened breastfeeding with early cessation within the fourth
month, described elsewhere [9,10,11]. All women could express
their infant feeding choice until birth and the staff supported their
choice and counseled them accordingly. These two options were
proposed free of charge including a controlled distribution of local
powdered infant formula (one box at each follow-up visit) from
birth or the date of weaning until nine months of age. Equipment
was provided free of charge to women willing to refrain from
breastfeeding: bottles, teats, cups, bottle brushes, pans to sterilize,
thermos to keep safely clean water. Women were also trained to
prepare and practice correctly formula-feeding [16]. Cup-feeding
was encouraged after four months of age. In March 2003, because
of the political turmoil in Co ˆte d’Ivoire, we stopped offering the
formula-feeding option, considering the risks of breakdown
distribution of the breast milk substitutes were ethically unaccept-
able and we oriented every new woman to the shortened
breastfeeding option until the end of the project, except if she
deliberately decided to formula-fed her child. A systematic vitamin
A supplementation was provided to children according to WHO
recommendations. HIV-infected children received a cotrimox-
azole prophylaxis systematically from six weeks of age until at least
their first birthday [17].
Follow-up procedures
Two clinics were exclusively dedicated to the follow-up of the
800 mother-infant pairs, with 60 health care workers recruited
from the local area and specifically trained for this program.
Pregnant women were followed weekly until delivery and mother-
infant pairs were seen 48 hours after birth, weekly until six weeks
of age, monthly until nine months of age, and every three months
until their second birthday. At each scheduled visit, clinical,
nutritional, psychosocial and biological follow-up of both mothers
and infants was proposed. Four nutritionists individually counseled
the women about safe infant feeding practices whenever needed.
Care services were also available whenever needed between
scheduled visits. All transport costs were reimbursed and all care
expenses related to any scheduled visit or clinical event were
entirely supported by the project.
Pediatric blood samples were taken for pediatric HIV-1
diagnosis at Day 2, week 4–6, then three monthly until one year,
month 18 and 24 and two months after complete cessation of
breastfeeding if any. A pediatric HIV-1 infection case was initially
diagnosed using a commercial plasma HIV-1 RNA assay (Versant
bDNA HIV RNA kit version 3.0, Bayer diagnostics, Emeryville,
CA, USA) [18], then from 2003, a TaqMan HIV-1 RNA real-time
PCR test was used for this purpose, with a threshold set up to
preserve a 100% inter-assay reproducibility [19]. Pediatric HIV-1
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if aged $18 months, a positive HIV serology. Peri-partum
transmission was defined in a child with a negative PCR at Day
2 who was later positive at 4–6 weeks. Postnatal transmission (PT)
was defined as a child with a negative HIV-1 PCR from a sample
obtained at age .30 days who later became infected. At the end of
follow-up, children were no longer at risk for HIV infection when
they were either HIV-1 infected or uninfected while complete
cessation of breastfeeding was obtained for at least two months.
Data collection
At each scheduled visit, clinical events that occurred in both
mothers and children since the last visit were documented and
infant feeding practices were recorded via structured question-
naires by trained social workers who were not involved in
nutritional counseling [9]. Infants were classified at each scheduled
visit as breastfed, mixed-fed or formula-fed using 7-day recall
histories [20]. We used the WHO definitions to allow a better
comparability of results between studies [21,22].
Comparison group
We used for reference the pooled data of two consecutive series
of mother-infant pairs, first those randomized to the ZDV arm of
the ANRS 049a trial from 1995 to 1998 in Abidjan [1] and second
those receiving ZDV in an open-fashion on the same sites in 1999–
2000 [23]. Maternal ZDV was initiated at 36 weeks and continued
for seven days post-delivery. No ZDV was given to neonates. No
infant feeding intervention was promoted and prolonged and
unrestricted breastfeeding was the norm [7,24].
Statistical analysis
Every HIV-1 infected pregnant woman enrolled was eligible if
she gave a live-birth. The allocation to an ARV intervention was
on an intent-to-treat basis. The allocation to one infant feeding
group (formula-fed or shortened breastfed) was based on the actual
feeding option implemented at Day 2 after delivery whatever the
prenatal choice, as some of the mothers did not express their infant
feeding choice before delivery and some of the children were not
fed in their first 24 hours of life.
Cumulative transmission risks (CTRs) of paediatric HIV infection
or (HIV or death) combined were estimated using Turnbull method
for each peripartum scARV regimen and in each infant feeding
group defined at ages 6-week, 6-month and 18-month in an intent-
to-feed analysis [25]. The analysis was also stratified according to
maternal eligibility criteria for ART using 2003 WHO criteria
(WHO clinical stage 4 or WHO clinical stage 3 and CD4,350/
mm
3 or WHO clinical stage 1–2 and CD4,200/mm
3) [26]. Results
were expressed in percentages with their 95% Confidence Interval
(CI). When Turnbull CIs were not computable, Kaplan-Meier
estimates were used for CIs, which was satisfactory since intervals
between tests were less than three-month [25].
For the HIV infection analysis, all first live-born fed at least
once were included and death was a censoring event. For the HIV-
free survival analysis, all first live-births were included and the time
of the event was the earlier of infection or death. Infants who were
lost-to-follow-up before reaching study end points were censored
at their last HIV-negative test. The competing risk analysis usually
recommended in breastfed children [25] was not applicable as part
of the children was not breastfed at all.
Effectiveness was expressed as 1 minus the ratio of estimated
CTR of HIV or death in the intervention group compared to the
reference group. Determinants for 18-month infection or death
were explored using a Cox model with the following variables:
peripartum ARV regimen combined with infant feeding option,
place and mode of delivery, maternal eligibility for ART, and low-
birth weight as a proxi of prematurity. A stepwise backward
multivariate analysis included all variables with p,0.25 in the
univariate analysis. Our study protocol implied that the treatment
was initiated earlier in the ZDV+3TC+sdNVP cohort (32 weeks)
than in the ZDV+sdNVP cohort (36 weeks). As a consequence, the
duration of prenatal prophylaxis was strongly correlated with the
antiretroviral drug regimen. The variable ‘cohort’ used in the Cox
model analysis took into account both the duration of prenatal
prophylaxis and the antiretroviral drug regimen used. For this Cox
model, time to infection was estimated to the first positive test or
the mid-point between the last negative test and the first positive
test when possible. All statistical analyses were carried out with the
SAS software (version 9.1; SAS Institute, Inc, Cary, NC, USA).
Results
Study population
Between March 6th 2001 and July 31st 2003, 808 women were
included in the ANRS 1201/1202 Ditrame-Plus cohorts (Table 1).
After exclusion of pregnant women lost-to-follow-up prior to
delivery, multiple birth outcomes, and stillbirths, 711 first live-born
children were enrolled: 375 received ZDV+sdNVP and 336
ZDV+3TC+sdNVP and were either formula-fed or short-term
breastfed. From September 1995 to 1998, 249 first live-born
children whose mother received ZDV alone were included in the
historical cohort in the same Abidjan health facilities. Among
those, only eight (3%) were formula-fed at that time and were
excluded, leaving 241 children exposed to ZDV and long-term
breastfeeding as the reference group. Overall, among the 952 first-
live born enrolled, 24 with no blood sample available (2.5%) and
two that could not be classified for infant feeding modalities at Day
2 were excluded from the present analysis (Table 1).
At baseline, women from the Ditrame-Plus cohorts were more
advanced in HIV-disease progression compared to the ZDV
historical cohort (Table 2): 17% of women in the Ditrame-Plus
cohorts had CD4,200 while this proportion was 11% in the ZDV
cohort. Similarly, the proportion of women eligible for ART and the
plasmaHIV-RNAviral load wassignificantly higherinthe Ditrame-
Plus cohorts than in the ZDV cohort. The median prenatal duration
of ARV prophylaxis increased significantly over time, from 20 days
in the ZDV cohort to 29 in the ZDV+sdNVP cohort and up to 50 in
the ZDV+3TC+sdNVP cohort (Table 2). The proportion of women
taking the ARV labour dose increased from 83% with ZDV alone to
93% with the two ARV combinations (p,10
24). There was no
statistical difference between the three groups for place of delivery,
the frequency of C-section and the frequency of low birth-weight.
However, within the Ditrame-Plus cohorts, women who initiated
breastfeeding delivered morefrequentlyathome thanthosefromthe
formula-fed group, 14.2% versus 5.6%, respectively in each ARV
intervention cohort.
The 238 ZDV children from the historical ZDV cohort were
predominantly breastfed for a median duration of 7.3 months in the
(IQR: 6–10) and defined as ‘‘long-term breastfed’’. In this cohort
predominant breastfeeding was the norm with early introduction of
water from day one in median [9]. In Ditrame-Plus, among the 688
children included in this analysis, 321 (47%) children were formula
fed of whom 47 (15%) women failed to maintain exclusive formula-
feeding and breastfed at least once. In Ditrame-Plus, 367 (53%)
children were short-term breastfed for a median duration of 3.9
months (IQR: 3–8) in scZDV+sdNVP children and 4.4 months
(IQR: 4–7) in sc(ZDV+3TC)+sdNVP children. Infant feeding
practices in Ditrame-Plus were extensively described elsewhere
[9,10]. When the formula feeding option was not offered any more
to new women included from March 2003 to July 2003, we did not
Prevent HIV Transmission
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children (similar mixed feeding practices and exclusive breastfeeding
behaviour). In the two Ditrame-Plus formula-feeding cohorts, 47
(15%) women failed to maintain exclusive formula-feeding and
breastfed at least once. At the end of the follow-up, 96.2% of the
formula-fed children wereno longer atriskfor HIV-1infection while
this proportion was only 84.7% in the three breastfed cohorts,
because of the longer duration of breastfeeding (p,10
26).
18-month cumulative rates of HIV transmission
At age 18-month, 107 children were HIV-1 infected of whom
30 (28%) were postnatal transmission cases (two in the formula-fed
groups), 70 (68%) were peripartum infections and seven (7%)
remained of unknown timing. Crude CTRs of infection at 18-
month using Turnbull estimates were 22.3% (95%CI: 16.1%–
29.8%) in the 238 ZDV long-term breastfed reference group,
13.4% (95%CI: 8.9%–19.9%) in the ZDV+sdNVP cohort
(irrespective of postnatal intervention) and 6.3% (95%CI: 3.8%–
9.1%) in the ZDV+3TC+sdNVP cohort, also irrespective of
postnatal intervention (Table 3). CTRs of infection at 18-month
were lower in formula-fed children than shortened breastfed
children, but this difference was less marked after
ZDV+3TC+sdNVP peripartum exposure than after ZDV+sdNVP
peripartum exposure. When stratifying the sample according to
the 2003 WHO criteria for maternal ART eligibility, all CTRs of
infection at 18-month were consistently 2 to 3 times higher among
ART-eligible mothers than those who were not (Table 3).
18-month cumulative rates of HIV transmission or death:
effectiveness
Among the 24 children with an indeterminate HIV status, 16
died. Among the 950 children exposed to HIV or death and
classified for infant modality, 149 were HIV-1 infected or dead at
age 18-month. At 18-month, crude CTRs of infection or death
using Turnbull estimates were 24.5% (95%CI: 19%–30%) in the
241 ZDV reference group, 16.8% (95%CI: 13%–21%) in the 375
ZDV+sdNVP group and 11.1% (95%CI: 8%–15%) in the 334
ZDV+3TC+sdNVP group.
Table 1. Number of women and children by peri-partum short-course (sc) antiretroviral regimen and infant-feeding modality for
prevention of Mother-To-Child transmission (PMTCT) of HIV.
Cohort (Period of inclusion)
DITRAME ZDV
(1994–1999)
Ditrame-Plus ZDV+sdNVP (2001–
2002)
Ditrame-Plus ZDV+3TC+sdNVP
(2002–2003) Total
Women enrolled 261 420 388 1069
Excluded (HIV-2 infection only or HIV not
confirmed)
01 8 1 6 3 4
Lost-to-follow-up before delivery (%) 8 (3.0) 21 (5.0) 23 (5.9) 52
Women who gave birth 253 381 349 983
Multiple birth outcomes excluded (stillbirths) 3 (0) 21 (1) 17 (0) 41
Stillbirths (%) 4 (1.5) 6 (1.6) 13 (3.7) 23
Live births included in the analysis 241* (100%) 375 (100%) 336 (100%)** 952**
Mortality: number of deaths among live-born
children (%)
33 (13.7) 35 (9.3) 22 (6.5) 90
Before Day 8 3 6 7 16
Day 8–Day 27 0 0 2 2
Day 28–Day 365 24 23 13 60
12 months–18 months 6 6 0 12
Not tested for paediatric HIV-1 infection (%) 3 (1.2) 11 (2.9) 10 (2.9) 24
Included in the HIV-transmission analysis 238 (100%) 364 (100%) 326 (100%) ** 928**
HIV-1 infection (%) 47 (19.8) [100%] 40 (11.0) [100%] 20 (6.1) [100%] 107
Peri-partum infection (,week 4) [%] 28 [60] 25 [63] 17 [85] 70
Postnatal infection ($week 4) [%] 15 [32] 13 [32] 2 [10] 30
Timing of infection unknown [%] 4 [8] 2 [5] 1 [5] 7
Infant feeding modality unknown 0 0 2 2
Included in the HIV-transmission analysis
according to infant feeding modality
Long-term breastfed
N=238
Formula-fed
N=195
Shortened breastfed
N=169
Formula-fed
N=126
Shortened breastfed
N=198
926**
HIV-1 infected (%) 47 (19.8) [100%] 18 (9.2) [100%] 22 (13.0) [100%] 7 (5.6) [100%] 13 (6.6) [100%] 107
Peri-partum infection (,week 4) [%] 28 [60] 16 [89] 9 [41] 7 [100] 10 [77] 70
Postnatal infection ($week 4) [%] 15 [32] 2 [11] 11 [50] 0 [0] 2 [15] 30
Timing of infection unknown [%] 4 [8] 0 [0] 2 [9] 0 [0] 1 [8] 7
ANRS 1201/1202 Ditrame-Plus and ANRS 049a DITRAME cohorts, Abidjan, Co ˆte d’Ivoire.
ZDV=short-course zidovudine; sdNVP=single-dose nevirapine during labour; 3TC=lamivudine.
*Eight formula-fed children were excluded.
**Two children were not classified for infant feeding modality.
doi:10.1371/journal.pone.0001645.t001
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PLoS ONE | www.plosone.org 5 February 2008 | Volume 3 | Issue 2 | e1645Determinants of 18-month effectiveness compared to
the ZDV long-term breastfed cohort
The crude analysis of 18-month HIV transmission or death
showed that the type of scARV regimen, low maternal CD4 count,
advanced maternal clinical staging, maternal eligibility for ART,
high maternal plasma viral load at inclusion, longer duration of
pre-partum scARV prophylaxis, higher gestational age, home
delivery, and low-birth weight, were significantly associated with
HIV-infection or death (Table 4). The pre-partum scARV
duration was highly correlated to the three ARV regimens,
without any significant interaction (p ranging from 0.08 to 0.75).
There was neither any interaction between ARV prophylaxis and
gestational age (p ranging from 0.26 to 0.94), nor between
treatment and home delivery (p ranging from 0.61 to 0.99). Using
the ZDV long-term breastfed cohort as the reference (24.5% HIV
transmission or death at 18 months), the protective effect of each
of the scARV combinations was strong for all combinations except
for the ZDV+sdNVP shortened breastfed children, with an
adjusted non-significant effectiveness of 32% (0%–60%) just below
the significant level. The adjusted effectiveness was significantly
higher for the others combined peri-partum and post-partum
regimens: 51% (20%–70%) for ZDV+sdNVP formula-fed chil-
dren, 63% (40%–80%) for ZDV+3TC+sdNVP shortened
breastfed children and 57% (20%–80%) for ZDV+3TC+sdNVP
formula-fed children after adjustment for maternal eligibility
criteria for ART, home delivery and low birth-weight in the final
adjusted model (Table 4).
Determinants of 18-month occurrence of HIV-infection or
death within Ditrame-Plus
Within the Ditrame-Plus cohorts, the final model analyzing
determinants of HIV-infection or death showed that the 3TC-
containing regimen tended to be protective but was no statistically
significant. In comparison with the ZDV+sdNVP as the reference,
the adjusted protective effect of ZDV+3TC+sdNVP on long-term
infection or death was not significant, 34% (95% CI:0%–60%,
p=0.06). Others risk factors of HIV-infection or death were the
maternal ART eligibility criteria (aHR: 2.15; CI:1.4–3.3,
p=0.0003), home delivery (aHR: 1.88; CI:1.1–3.2, p=0.02) and
low-birth-weight (aHR: 2.50; CI:1.5–4.0, p=0.0002) (Table 5).
Formula-feeding was not a significant determinant of HIV-
transmission or death compared to shortened breastfeeding
(aHR: 0.85; CI:0.6–1.3, p=0.46).
Discussion
The absolute long-term efficacy of all scARV regimens
administrated in peripartum in African breastfeeding populations
is likely to be reduced beyond 4–6 weeks because of the
breastfeeding HIV transmission [7]. We have previously reported
on the short-term efficacy at age 6-week of two scARV
combination regimens, ZDV+sdNVP and ZDV+3TC+sdNNVP
[8]. Alternatives to prolonged breastfeeding are aimed to optimize
the long-term efficacy of these peri-partum ARV regimens. We
report here that a significant reduction of MTCT of HIV can be
achieved, with these scARV interventions combined with two
different alternatives to prolonged breastfeeding, with a long-term
benefit sustained until age 18-month and without any increasing
risk of death.
Several arguments justified the Ditrame-Plus study design. First,
we chose a non-randomized approach to estimate the treatment
effect as we considered there was a priori lack of equipoise between
ZDV+sdNVP and ZDV alone. We hypothesized the addition of
sdNVP to ZDV would be efficient by its partially different
mechanism of action, and did not anticipate tolerance issues based
Table 3. Estimated cumulative transmission risk (CTR) and 95% confidence interval (CI) of HIV-1 infection diagnosis at age 18
months in live-born children.
Cohort
DITRAME ZDV Long-term
breastfed I/n=47/238 Ditrame-Plus ZDV+sdNVP I/n=40/364
Ditrame-Plus ZDV+3TC+sdNVP I/
n=20/326 **
6 weeks 13.2 (7.2–17.4) 8.9 (5.3–12.3) 5.9 (3.4–8.5)
6 months 18.9 (12.9–24.3) 9.7 (6.5–12.7) 6.3 (3.8–9.1)
18 months 22.3 (16.1–29.8) 13.4 (8.9–19.9) 6.3 (3.8–9.1)
Infant-feeding modality Long-term breastfed Formula-fed Shortened breastfed Formula-fed Shortened breastfed
I/n=47/238 I/n=18/195 I/n=22/169 I/n=7/126 I/n=13/198
6 weeks 13.2 (7.2–17.4) 9.4 (4.8–13.6) 8.6 (2.9–13.2) 5.6 (1.6–9.6){ 6.2 (3.1–9.9)
6 months 18.9 (12.9–24.3) 9.4 (5.1–13.6) 10.1 (5.5–14.9) 5.6 (1.6–9.6){ 6.8 (3.6–10.7)
18 months 22.3 (16.1–29.8) 9.4 (5.5–13.6) 15.9 (9.6–26.5) 5.6 (1.6–9.6){ 6.8 (3.6–10.7)
Mothers eligible for ART* I/n=16/36 I/n =10/62 I/n=9/41 I/n=3/26 I/n=5/40
6 weeks 26.2 (11.4–40.9){ 16.3 (7.1–25.6){ 10.1 (0.7–19.6){ 11.5 (0–23.8){ 13.0 (2.3–23.7){
6 months 41.6 (24.8–58.3){ 16.3 (7.1–25.6){ 15.9 (4.2–27.7){ 11.5 (0–23.8){ 13.0 (2.3–23.7){
18 months 48.1 (30.9–65.2){ 16.3 (7.1–25.6){ 25.2 (10.8–39.6){ 11.5 (0–23.8){ 13.0 (2.3–23.7){
Mothers not eligible for ART* I/n=29/196 I/n=8/133 I/n=13/126 I/n=4/100 I/n=8/157
6 weeks 9.3 (5.2–13.4){ 4.5 (1.0–8.0){ 4.9 (1.1–8.7){ 4.0 (0–7.9){ 4.0 (0.9–7.0){
6 months 13.6 (8.7–18.5){ 6.2 (2.0–10.3){ 8.3 (3.4–13.2){ 4.0 (0–7.9){ 5.4 (1.8–9.1){
18 months 15.5 (10.3–20.7){ 6.2 (2.0–10.3){ 11.1 (5.4–16.8){ 4.0 (0–7.9){ 5.4 (1.8–9.1){
ANRS 1201/1202 Ditrame-Plus and ANRS 049a DITRAME cohorts, Abidjan, Co ˆte d’Ivoire, 2001–2005. Turnbull estimates and Kaplan-Meier estimates.
I/n: number of children infected/number of children at risk for mother-to-child transmission.
*ART=antiretroviral therapy if WHO clinical stage 4 or WHO clinical stage 3 and CD4,350/mm
3 or WHO clinical stage 1/2 and CD4,200/mm
3.
**Two children were not classified for infant feeding modality. { Confidence interval based on Kaplan-Meier estimates.
doi:10.1371/journal.pone.0001645.t003
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PLoS ONE | www.plosone.org 6 February 2008 | Volume 3 | Issue 2 | e1645on the HIVNET 012 trial findings [4]. In addition, as Ditrame-
Plus women were enrolled and followed on the same sites than in
the previous Ditrame trial cohort, we estimated that we would be
able to control for the most important confounding factors and
determinants of MTCT or death that were prospectively
measured, such as maternal clinical and immunological HIV
disease staging, mode of delivery, breastfeeding exposure and
duration of the ARV prophylaxis. Second, we assessed the field
effectiveness of the two infant feeding options in a sample
representative of childbearing age women living in an urban
African setting with water access. We chose a cohort design instead
of a randomized clinical trial, to avoid the allocation of the infant
feeding practices at random and then minimize the ethical
considerations and the risk of non compliance inducing at-risk
mixed feeding-practices, as previously reported [27,28]. However,
our results must be interpreted with caution given the well
Table 4. Determinants of 18-month HIV-1 infection or death (Cox proportional hazard model; reference: ZDV long-term breastfed).
Variables Crude (Univariate) Adjusted (Multivariate*)
N=950 CTR
1 95% CI HR# 95% CI p
11 HRa 95% CI p
Cohort # 0.003 0.0001
ZDV long-term breastfed (reference) 241 24.5 19–30 1 - 1 -
ZDV+sdNVP shortened breastfed 177 18.4 12–24 0.72 0.5–1.3 0.68 0.4–1.1
ZDV+sdNVP formula-fed 198 15.8 9–22 0.56 0.4–0.9 0.49 0.3–0.8
ZDV+3TC+sdNVP shortened breastfed 203 10.4 6–15 0.41 0.2–0.7 0.37 0.2–0.6
ZDV+3TC+sdNVP formula-fed 131 12.3 7–18 0.49 0.3–0.9 0.43 0.2–0.8
Maternal CD4 count ,0.0001
[0–200] 146 27.9 21–35 3.08 1.9–4.9
[200–350] 234 20.4 15–26 2.08 1.3–3.3
[350–500] 232 14.1 10–19 1. 39 0.9–2.3
$500 338 11.2 7–15 1 -
Maternal clinical HIV stage 0.0034
1–2 738 14.9 12–18 1 -
3 207 23.0 17–29 1.69 1.2–2.4
4 5 40.0 0–83 3.80 0.9–15.4
Not eligible for ART 729 13.7 11–17 1 - 1 -
Eligible for ART 212 27.0 21–33 2.25 1.6–3.1 ,0.0001 2.54 1.8–3.6 ,0.0001
Maternal plasma viral load (for one log increase) - - - 2.47 2.0–3.1 ,0.0001
Maternal age (for +10 years) - - - 1.14 0.9–1.5 0.39
Prepartum prophylaxis 0.018
,30 days 426 20.5 16–25 1 -
30 days and more 524 13.8 11–17 0.68 0.5–0.9
Parity (for one unit increase) - - - 1.02 0.9–1.1 0.73
Primigravida 0.77
No 136 16.6 14–19 1 -
Yes 13 19.1 10–28 1.09 0.6–1.9
Gestational age at inclusion (for one week increase) - - - 1.06 0.9–1.1 0.16
Delivered at home ,0.0001 0.0005
No 839 14.9 12–18 1 - 1 -
Yes 109 32.4 23–42 2.30 1.5–3.4 2.04 1.4–3.1
C-section 0.80
No 901 16.9 14–20 1 -
Yes 47 15.2 5–26 0.91 0.4–1.9
Low birth-weight (,2500 g) 0.0001 0.0002
No 825 15.1 12–18 1 - 1 -
Yes 120 27.3 19–35 2.15 1.5–3.2 2.18 1.5–3.3
ANRS 1201/1202 Ditrame-Plus and ANRS 049a DITRAME cohorts, Abidjan, Co ˆte d’Ivoire.
*Variables with p,0.25 in the comparison of the three treatment groups (table 2).
1Estimated cumulative transmission risk (CTR) of HIV-1 infection at 18-month using
Kaplan-Meier estimates.
11Log-rank test; CI: confidence interval;
#univariate=unadjusted Cox proportional hazards model; HR: hazard ratio; HRa: adjusted Hazard Ratio;
3TC=lamivudine; sdNVP=single-dose nevirapine during labour; ZDV =zidovudine. ART=highly active antiretroviral therapy if WHO clinical stage 4 or WHO clinical
stage 3 and CD4,350 /mm
3 or WHO clinical stage 1/2 and CD4,200/mm
3. #in the adjusted analysis, this variable took into account both the treatment duration and
the antiretroviral regimen used.
doi:10.1371/journal.pone.0001645.t004
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PLoS ONE | www.plosone.org 7 February 2008 | Volume 3 | Issue 2 | e1645accepted limitations of use of historical control data and multiple
non-randomized comparison groups. While the multivariate
analysis can control for some of these differences and the main
known MTCT risk factors, it was not possible to control for all
possible confounders. Anyway, using the combined outcome of
HIV-free survival, our study helps assessing the public health
effectiveness of the combination of scARV regimens with
alternatives to prolonged breastfeeding and answering to the
following issues. Do alternatives to prolonged breastfeeding
(formula feeding and shortened breastfeeding) decrease MTCT
versus prolonged breastfeeding after using scARV regimens
without increasing death? Does formula feeding prevent more
infections than 4-month breastfeeding after using scARV regi-
mens? What is the effectiveness on MTCT of adding 3TC to
ZDV+sdNVP?
First, we demonstrated that both formula feeding from birth
and shortened breastfeeding, combined with any scARV com-
bined regimens decreased significantly the 18-month risk of HIV
Table 5. Determinants of 18-month HIV-1 infection or death (Multivariate Cox proportional hazard model, reference: ZDV+sdNVP).
Variables Crude (Univariate) Adjusted (Multivariate*)
N=709 CTR
1 95% CI HR# 95% CI p
11 HRa 95% CI p
Cohort # 0.09 0.06
ZDV+sdNVP (reference) 375 16.8 13–21 1 - 1
ZDV+3TC+sdNVP 334 11.1 8–15 0.70 0.5–1.1 0.66 0.4–1.0
Infant feeding 0.87 0.46
Shortened breastfed (reference) 380 14.2 11–18 1 - 1
Formula-fed 329 14.3 10–19 0.97 0.6–1.5 0.85 0.6–1.3
Maternal CD4 count 0.0003
[0–200] 119 23.6 16–31 3.75 2.0–7.1
[200–350] 188 16.9 12–22 2.49 1.3–4.6
[350–500] 180 11.8 7–17 1.67 0.9–3.3
$500 222 8.6 4–14 1 -
Maternal clinical HIV stage 0.0007
1–2 530 11.8 9–15 1 -
3 174 20.7 15–27 1.98 1.3–3.0
4 5 40.0 0–83 4.78 1.2–19.6
Eligible for HAART 176 22.3 16–29 2.23 1.5–3.4 0.0001 1 0.0003
Not eligible for HAART 530 11.5 8–15 1 - 2.15 1.4–3.3
Maternal viral load (for one log increase) - - - 2.54 2.0–3.3 ,.0001
Maternal age (for +10 years) - - - 1.11 0.8–1.6 0.59
Prepartum treatment (for 10 days increase) 0.88 0.8–0.98 0.019
Parity (1 increase) 0.56
Primigravida 0.75
No 653 14.0 11–17 1 -
Yes 56 16.9 6–28 1.13 0.5–2.3
Gestational age at inclusion (for one week
increase)
1.02 0.9–1.1 0.73
Delivered at home 0.0025 0.02
No 636 12.7 10–16 1 - 1
Yes 73 27.4 17–38 2.22 1.3–3.7 1.88 1.1–3.2
C-section 0.66
No 671 14.0 11–17 1 -
Yes 38 16.0 4–28 1.21 0.5–2.8
Low birth-weight (,2500 g) 0.0002 0.0002
No 617 12.3 9–15 1 - 1
Yes 91 25.6 27–35 2.48 1.5–4.0 2.50 1.5–4.0
ANRS 1201/1202 Ditrame-Plus, 2001–2005, Abidjan, Co ˆte d’Ivoire.
*Variables with p,0.25 in the comparison of the three treatment groups (table 2).
1Estimated cumulative transmission risk (CTR) of HIV or death at 18 months using
Kaplan-Meier estimates (%).
11logrank test;
#univariate analysis=unadjusted Cox proportional hazards model; CI confidence interval; HR hazard ratio; HRa adjusted
Hazard Ratio; 3TC=lamivudine; NVPsd=single-dose nevirapine during labour; ZDV =zidovudine. HAART=highly active antiretroviral therapy if WHO clinical stage 4 or
WHO clinical stage 3 and CD4,350/mm
3 or WHO clinical stage 1/2 and CD4,200/mm
3. #in the adjusted analysis, this variable took into account both the treatment
duration and the antiretroviral regimen used.
doi:10.1371/journal.pone.0001645.t005
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PLoS ONE | www.plosone.org 8 February 2008 | Volume 3 | Issue 2 | e1645transmission when compared to long-term breastfeeding combined
with ZDV (data not shown). Using the reference group of children
exposed to maternal ZDV regimen and prolonged breastfeeding,
our results confirm the greater effectiveness of ZDV+sdNVP and
ZDV+3TC+sdNVP combined with any infant feeding option
(formula-feeding or shortened breastfeeding) in increasing HIV-
free survival, after adjustment on other MTCT determinants, with
significant reductions ranging from 51% to 73%, except for the
shortened breastfed ZDV+sdNVP cohort comparable to the
reference group. To formally distinguish the effect of the postnatal
interventions from the scARV intervention, a reference group of
children exposed to ZDV and formula-feeding would have been
necessary. However, they constituted a sample too small to
provide reliable information (n=8), and we preferred to exclude
them from the analysis.
These results confirm our previously published 6 weeks
transmission analysis [8]. The most effective of these scARV
strategies could thus lead to residual long-term MTCT risks lower
than 5%, in children born to mother not fulfilling eligibility criteria
for ART and even after exposure to shortened breastfeeding. To our
knowledge, this is the first time that such a PMTCT long-term
outcome is reported in breastfeeding populations, and these
encouraging results are close to those observed in developed
countries with more complex PMTCT strategies. We can therefore
conclude that both postnatal interventions, formula feeding from
birth and shortened 4-months breastfeeding, were effective in
increasing HIV-free survival in this context. HIV-infected women
should choose the one adapted to their individual situation.
Second, within the Ditrame-Plus cohort, formula feeding may
be slightly better than shortened 4-months breastfeeding combined
with scARVs but the difference was not statistically significant.
Third, when considering the HIV-free survival outcome within
the Ditrame-Plus cohort, the 3TC-based strategy was not
significantly protective, just below the type-1 error level, although
there was a tendency, probably by lack of statistical power. In fact,
the treatment duration differed also substantially between these
two cohorts because the scARV was initiated earlier among
women treated with ZDV+3TC+sdNVP (32 weeks) than in
women receiving ZDV+sdNVP (36 weeks). As a conclusion, we
were not able to distinguish the treatment effect from the duration
effect, but we conclude to an overall effectiveness of the 3TC
strategy. The longer the duration of the pre-partum
ZDV+3TC+sdNVP prophylaxis, the lower the 18-month MTCT
risk: this dose-effect relationship argues for a plausible causal
relationship between the cumulative drugs intake and their effect
in reducing durably the maternal plasma HIV viral load, a strong
determinant of mother-to-child transmission [29]. This effect was
already reported in the Thai ZDV+sdNVP trial with a significant
higher protective effect on HIV infection with longer ARV
prophylaxis in a non breastfeeding population [30]. The 18-month
residual MTCT rate in the Ditrame-Plus cohort exposed to
ZDV+sdNVP and formula feeding was higher (9.4%) than the one
measured in Thailand reaching 2% at 6–8 weeks [30]. This
discrepancy is probably related to the pre-partum duration of
ARV prophylaxis, beginning at 28 weeks of gestation in the
Thailand trial, i.e., four to eight weeks earlier than in Ditrame-
Plus, enough to lower efficiently the maternal HIV plasma viral
load. As a result, the earlier the maternal scARV regimen begins,
the lower the peripartum transmission rate is. This is in agreement
with the current 2006 WHO PMTCT guidelines [31].
Thus, the short-course peripartum ZDV+3TC regimen com-
bined with sdNVP from 32 weeks would be proposed as a valuable
option, particularly in women who choose to breastfed, consider-
ing also its ability in minimizing the emergence of NVP-resistance
[32]. However this combination was also associated with the risk of
emergence of 3TC resistance, 15% in our cohort, with potentially
adverse consequences for maternal health [32,33]. Indeed, we
reported that 3TC-resistance acquired after the exposition to a
PMTCT regimen is responsible for a significant virological failure
of the subsequent maternal response to HAART [33]. The longer
the duration of 3TC-exposure, the higher the risk of emergence of
resistance [34]. So, we conclude that ZDV+3TC regimen
combined with sdNVP should be kept as a late indication after
36 weeks. Consequently, our findings could have implications on
the 2006 WHO recommendations. If HIV-infected pregnant
women are eligible for HAART, they should receive it since with
very low MTCT rates can be achieved [35]. If they are not eligible
for HAART or if it is not available, then the strategy could be as
follows. If she is identified before 36 weeks of gestation, the
ZDV+sdNVP strategy should be proposed with a tail of 3 days
ZDV+3TC to reduce NVP-resistance. If she is identified from 36
weeks of gestation, the ZDV+3TC+sdNVP strategy should be
proposed with a tail of 3 days ZDV+3TC to reduce NVP-
resistance. Beyond any of these peri-partum interventions, post-
partum interventions should be associated.
The long-term effectiveness of peri-partum and post-partum
combined interventions needs to be balanced with their maternal
social acceptability, and their impact on 2-year health outcomes in
children: postnatal transmission, morbidity and mortality. The cost
issue of the postnatal interventions also needs to be addressed. In the
Ditrame-Plus cohort, we pragmatically used multiple judgment
criteria to assess infant feeding options. First, there was a high
acceptability of both alternatives to prolonged breastfeeding leading
to a real opportunity of controlling for the risk of HIV transmission
through breast-milk. Formula feeding was acceptable for half of the
women with less than 15% of failures (defined as breastfeeding at
least one) observed until one year, leading to few mixed-fed children
[10]. Among breastfeeding mothers, the duration of breastfeeding
was reduced to four months inmedian [9]. When assessing HIV-free
survival outcomes in formula-fed children compared to the long-
termbreastfed ones,our observation strengthens the safetyresults we
had reportedpreviously,withtwo-yearmorbidityand mortalityrates
similar between shortened breastfed and formula-fed children [11].
These two groups of children did not have either any excess
mortality compared to the long-term breastfed children of the
Ditrame cohort [11]. In this ‘‘long-term’’ breastfed group, the
breastfeeding duration was shorter than practices usually reported in
Africa (the median duration was 7.3 months), but we estimated the
difference in HIV-transmission or death in a very conservative way.
In the Mashi trial, HIV-free survival outcomes were comparable
between formula fed children and breastfed ZDV-exposed children:
breastfeeding after ZDV prophylaxis was not as effective as formula
feedinginpreventing postnatalHIV transmission,butwasassociated
with a lower mortalityrate than formula feeding at 7 months[36].In
our study, we conclude to the superiority of the effectiveness of the
combination of peri-partum interventions with alternatives to
prolonged breastfeeding.
However, it is crucial to bear in mind the conditions required to
consider safely alternatives to breastfeeding in an African context:
access to clean water as it was the case in this urban setting,
nutritional information and formulation of the maternal choice
during the prenatal period, equipment and formula feeding given
for free for at least for nine months, regular postnatal follow-up
with nutritional counseling and repeated growth measurements.
Given these conditions, it was appropriate to promote infant
feeding options to women in our settings. The most appropriate
infant feeding option for an HIV-infected mother should depends
on her individual circumstances, including her health status, the
Prevent HIV Transmission
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greater consideration of the health services available and the
counseling and support she is likely to receive, as recently
recommended by WHO [37]. Other postnatal interventions need
to be further investigated to prevent MTCT in Africa, such as
maternal ART while breastfeeding, either restricted to women
needing it for their own health or prescribed to all women during
breastfeeding with early cessation from six months [38]. Research
studies are needed to fully understand the impact of maternal
ARV treatment on the reduction of breastfeeding HIV-1
transmission, but also on infant toxicity and on acquisition of
HIV-1 resistance mutations among infected infants [38,39].
Alternatively, prolonging maternal and/or infant post-exposure
prophylaxis with scARV regimens deserves proper evaluation.
Altogether, we demonstrate in this large African urban cohort that
the risk reductions obtained with these relatively simple and
affordable scARV drug regimens combined with acceptable
alternatives to breastfeeding are getting closer to those observed in
developed countries, with a sustained long-term effect even in
shortened breastfed children. A decision analysis could be helpful in
guiding recommendations on the safest and best infant feeding
modalities according to the different African contexts combined with
the fullspectrumofARVstrategies,includingARTforthoseinneed.
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